Reference : Cabergoline in the treatment of acromegaly: a study in 64 patients.
Scientific journals : Article
Human health sciences : Endocrinology, metabolism & nutrition
http://hdl.handle.net/2268/24272
Cabergoline in the treatment of acromegaly: a study in 64 patients.
English
Abs, Roger [> > > >]
Verhelst, Johan [> > > >]
Maiter, Dominique [> > > >]
Van Acker, Kristien [> > > >]
Nobels, Frank [> > > >]
Coolens, Jean-Luc [> > > >]
Mahler, Charles [> > > >]
Beckers, Albert mailto [Université de Liège - ULg > Département des sciences cliniques > Endocrinologie >]
Feb-1998
Journal of Clinical Endocrinology and Metabolism
Endocrine Society
83
2
374-8
Yes (verified by ORBi)
International
0021-972X
Chevy Chase
MD
[en] Acromegaly/drug therapy ; Adenoma/secretion ; Adolescent ; Adult ; Aged ; Dopamine Agonists/therapeutic use ; Ergolines/adverse effects/therapeutic use ; Female ; Human Growth Hormone/secretion ; Humans ; Insulin-Like Growth Factor I/metabolism ; Male ; Middle Aged ; Pituitary Neoplasms/secretion ; Prolactin/secretion ; Prospective Studies
[en] Cabergoline is a new, long acting, dopamine agonist that is more effective and better tolerated than bromocriptine in patients with hyperprolactinemia. Because dopamine agonists still have a place in the medical management of acromegaly, cabergoline might be a useful treatment. We, therefore, evaluated the effect of long term administration of cabergoline in a large group of unselected acromegalic patients. Sixty-four patients were included in a multicenter, prospective, open labeled study. A subgroup of 16 patients had GH-/PRL-cosecreting pituitary adenomas. Cabergoline was started at a dose of 1.0 mg/week and was gradually increased until normalization of plasma insulin-like growth factor I (IGF-I) levels, occurrence of unacceptable side-effects, or a maximal weekly dose of 3.5 mg (7.0 mg in 1 case) was reached. Treatment with cabergoline suppressed plasma IGF-I below 300 micrograms/L in 39% of cases and between 300-450 micrograms/L in another 28%. With pretreatment plasma IGF-I concentrations less than 750 micrograms/L, a suppression of IGF-I below 300 micrograms/L was obtained in 53% of cases, and a suppression between 300-450 micrograms/L was obtained in another 32%. By contrast, with pretreatment plasma IGF-I concentrations above 750 micrograms/L, only 17% of cases showed a suppression of IGF-I below 300 micrograms/L, and there was IGF-I suppression between 300-450 micrograms/L in another 21%. In GH-/PRL-cosecreting adenomas, 50% of cases suppressed plasma IGF-I levels below 300 micrograms/L, and another 31% did so between 300-450 micrograms/L, in contrast to only 35% and 27%, respectively in GH-secreting adenomas. Similar results were obtained concerning the secretion of GH. Tumor shrinkage was demonstrated in 13 of 21 patients, with a mass reduction by more than half in 5 GH-/PRL-cosecreting adenomas. Except for slight gastrointestinal discomfort and orthostatic hypotension in a few patients at the beginning of therapy, cabergoline treatment was well tolerated. Only 2 patients stopped medication because of nausea. The weekly dose of cabergoline ranged between 1.0-1.75 mg. A further increase in the dose was only effective in 1 GH-/PRL-cosecreting adenoma. The results of this study suggest that cabergoline is an effective, well tolerated therapy that should be considered in the management of acromegaly, especially if the pituitary adenoma cosecretes GH and PRL or if pretreatment plasma IGF-I levels are below 750 micrograms/L.
Researchers ; Professionals
http://hdl.handle.net/2268/24272

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Cabergoline in the treatment of acromegaly.pdfNo commentaryPublisher postprint171.98 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.